Court Clears Teva After At-Risk Budesonide Entry

 
• By Aidan Fry

Teva has escaped potential damages from its ‘at risk’ US launch of budesonide extended-release tablets after a US Court of Appeals upheld a previous non-infringement ruling.

RiskReward
Teva has seen its decision to launch generic budesonide extended-release tablets 'at risk' in the US pay off • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin